• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.

作者信息

Thompson S J, Mellon K, Charlton R G, Marsh C, Robinson M, Neal D E

机构信息

Department of Pathology, Freeman Hospital, Newcastle upon Tyne.

出版信息

Br J Urol. 1992 Jun;69(6):609-13. doi: 10.1111/j.1464-410x.1992.tb15632.x.

DOI:10.1111/j.1464-410x.1992.tb15632.x
PMID:1379102
Abstract

Mutation of the p53 gene is one of the commonest genetic abnormalities found in solid human tumours. This gene is probably concerned with the control of cellular proliferation and in view of this we carried out a study of human prostate cancer and benign prostatic hyperplasia, comparing the expression of mutated p53 with measurement of growth fractions as assessed by staining with Ki-67. A series of 29 patients with prostate cancer (CaP) were compared with 34 men with benign hyperplasia (BPH); 22 of 29 prostate cancers (76%) contained Ki-67 immunoreactivity compared with 10 of 34 (29%) BPH. With respect to p53 staining, significantly more prostate cancers (17%) were stained than BPH (0%). The mean Ki-67 score in cancers positive for p53 (4.3%) was greater than that found in cancers negative for p53 (1.2%), but no statistically significant relationship was found between tumour grade and Ki-67 staining. The use of Ki-67 and p53 staining may allow identification of tumours with a higher rate of cell growth and may permit development of prognostic factors.

摘要

相似文献

1
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.
Br J Urol. 1992 Jun;69(6):609-13. doi: 10.1111/j.1464-410x.1992.tb15632.x.
2
Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.前列腺癌和前列腺上皮内瘤变中p53蛋白的免疫组织化学测定
Urol Int. 1997;58(4):199-202. doi: 10.1159/000282983.
3
Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.Ki-67抗原与P53蛋白在前列腺良恶性病变中的表达:免疫组织化学定量研究
Pol J Pathol. 2000;51(1):31-6.
4
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.良性和恶性前列腺组织中的p53、c-erbB-2与表皮生长因子受体
J Urol. 1992 Feb;147(2):496-9. doi: 10.1016/s0022-5347(17)37287-7.
5
Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.Ki-67和PCNA在前列腺癌和良性前列腺增生中的表达
Clin Invest Med. 2008;31(1):E8-E15. doi: 10.25011/cim.v31i1.3136.
6
Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.视网膜母细胞瘤和p53肿瘤抑制基因在前列腺上皮内瘤变中的免疫组化表达:与前列腺腺癌和良性前列腺的比较。
Mod Pathol. 1998 Mar;11(3):247-52.
7
Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study.
Br J Urol. 1996 Mar;77(3):441-4. doi: 10.1046/j.1464-410x.1996.85721.x.
8
Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.干扰素-γ及其功能性受体在良性前列腺增生和前列腺癌中的过表达:与c-myc和p53表达的平行关系
Eur Cytokine Netw. 2000 Mar;11(1):119-27.
9
p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.p53蓄积与bcl-2、增殖标志物MIB-1以及接受密切观察等待的前列腺癌患者的生存率相关。
J Urol. 2000 Sep;164(3 Pt 1):716-21. doi: 10.1097/00005392-200009010-00023.
10
Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.恶性和良性前列腺组织中TP53基因突变的基因检测与免疫检测的相关性
Hum Pathol. 1996 Jun;27(6):573-80. doi: 10.1016/s0046-8177(96)90164-1.

引用本文的文献

1
A Study of Ki-67 Immunostaining in Prostate Carcinomas and Its Correlation with Gleason's Score and Prognosis: An Experience at a Tertiary Centre in the Himalayan Foothills.前列腺癌中Ki-67免疫染色及其与Gleason评分和预后的相关性研究:喜马拉雅山麓一家三级中心的经验
Indian J Surg Oncol. 2024 Jun;15(2):341-348. doi: 10.1007/s13193-024-01902-4. Epub 2024 Feb 21.
2
Telomeres and telomerase in prostate cancer development and therapy.端粒与端粒酶在前列腺癌发生发展及治疗中的作用
Nat Rev Urol. 2017 Oct;14(10):607-619. doi: 10.1038/nrurol.2017.104. Epub 2017 Jul 4.
3
Significance of p53 and ki-67 expression in prostate cancer.
p53和ki-67在前列腺癌中的表达意义
Urol Ann. 2015 Oct-Dec;7(4):488-93. doi: 10.4103/0974-7796.158507.
4
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.人类前列腺癌的差异表达基因和标志性通路
PLoS One. 2015 Dec 18;10(12):e0145322. doi: 10.1371/journal.pone.0145322. eCollection 2015.
5
Clinical significance of nuclear p53 protein accumulation in bladder cancer.核p53蛋白在膀胱癌中积累的临床意义
Int Urol Nephrol. 1999;31(3):327-34. doi: 10.1023/a:1007122118882.
6
Implication of cell kinetic changes during the progression of human prostatic cancer.细胞动力学变化在人类前列腺癌进展过程中的意义。
Clin Cancer Res. 1995 May;1(5):473-80.
7
Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies MIB-1 and DO-7 in formalin-fixed paraffin-embedded tumour material.Ki-67抗原和p53蛋白表达在胰腺导管癌中的预后意义:对福尔马林固定石蜡包埋肿瘤材料中单抗MIB-1和DO-7的研究
Br J Cancer. 1997;76(1):54-9. doi: 10.1038/bjc.1997.336.
8
Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.细胞核p53过表达与移行细胞膀胱癌临床及组织病理学特征的相关性
Int Urol Nephrol. 1997;29(1):25-31. doi: 10.1007/BF02551413.
9
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.前列腺癌转移的分子标志物。开发预测前列腺癌侵袭性的诊断方法。
Am J Pathol. 1997 May;150(5):1511-21.
10
Ki-67 expression in early prostate cancer and associated pathological lesions.Ki-67在早期前列腺癌及相关病理病变中的表达
J Clin Pathol. 1996 Sep;49(9):741-8. doi: 10.1136/jcp.49.9.741.